Financial Services
Drugs Made In America Acquisition Corp. Rights(DMAAR)
Live Price
Offline$0.10
+0.00% today
1Y Change
-23.08%
Window
Jun 26, 2025 → Jun 23, 2026
- Market Cap
- $360.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +439.3%
- Dividend Yield
- 0.0%
Coverage: 209 bars · Jun 26, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Drugs Made In America Acquisition Corp. Rights (DMAAR) is a Financial Services stock with a market cap of $360.00M and listed on NASDAQ. The stock last traded around $0.10 and down 23.1% across the available one-year price window (Jun 26, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +439.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +439.3%, free cash flow -182675.3% with operating margin 0.0% and ROIC -1.2%. Valuation already assumes a fairly strong business story at P/E 37.4. Stock Foundry combines DMAAR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +3.4% peer median
Operating Margin
Below sector median
0.0% vs +4.7% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +439.3%, while operating margin sits near 0.0%.
Benchmark Edge
DMAAR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DMAAR
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DMAAR Max Drawdown
-81.09%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DMAAR and SPY.
Company Overview
Drugs Made In America Acquisition Corp. Rights
NASDAQ Global Select
Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
- Leadership
- Roger Bendelac
- Street Address
- 1 East Broward Blvd Suite 700
- Mailing
- Fort Lauderdale, FL, 33301
- Region
- Fort Lauderdale, FL, US
- Reporting Currency
- USD
- Investor Line
- +1 212 906 1222
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 37.4
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- 1.0
Growth
- Revenue
- 0.0%
- EPS
- +439.3%
- Free Cash Flow
- -182675.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 2.6%
- ROIC
- -1.2%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.